IBD Science for Patients

If you live with ulcerative colitis, bowel urgency is often one of the most stressful and disruptive symptoms you face. The sudden, unpredictable need to rush to a toilet can make leaving the house, going to work, or enjoying social events feel daunting. For years, standard medical trials focused almost entirely on counting daily stool frequency, often overlooking the emotional toll and sudden panic that bowel urgency creates.

Now, results from a clinical trial named the LUCENT-URGE study, published in the journal Crohn’s & Colitis 360 and PubMed, bring encouraging news. The study demonstrates that an advanced biologic medication named mirikizumab delivers rapid, long-lasting reductions in bowel urgency, giving patients vital extra time to reach a restroom comfortably.

Demystifying the Science: How Mirikizumab and Urgency Tracking Work

To understand why this study represents a major step forward for patient care, it helps to break down the medication and the novel measuring tools used by the research team:

• Mirikizumab (Omvoh): An advanced biological therapy known as an IL-23p19 inhibitor. It acts like a precision key that blocks interleukin-23, a specific inflammatory protein signal in your immune system that drives gut lining swelling and tissue irritation.
• Urgency Numeric Rating Scale (UNRS): A validated 0-to-10 scoring system where patients rate their bowel urgency severity each day, with 0 meaning no urgency and 10 representing the worst imaginable urgency.
• Bowel Urgency Frequency (BUF): A novel measurement that tracks the exact number of times a patient experiences sudden, urgent needs to use the toilet in a 24-hour period.
• Stool Deferral Time (SDT): A groundbreaking measure that records how long a patient can comfortably delay a bowel movement once the urge strikes (for example, holding for at least 15 minutes), or whether they experience total freedom from urgency over a full day.
• Histologic-Endoscopic Mucosal Improvement (HEMI): The ultimate goal of tissue healing. It combines a healthy visual appearance of the bowel wall during a camera check (endoscopy) with microscopic proof under a laboratory microscope that inflammatory cells have cleared from tissue samples.

Inside the Study: 172 Patients Monitored Over 28 Weeks

The LUCENT-URGE study was a large-scale, multicentre, open-label Phase 3b trial conducted across international inflammatory bowel disease centres.

The trial enrolled 172 adult patients with moderately to severely active ulcerative colitis who experienced significant bowel urgency at the start of the study. Participants received intravenous mirikizumab infusions at weeks 0, 4, and 8 (the induction phase), followed by monthly subcutaneous injections through week 24, with full health evaluations conducted at Week 28 (7 months).

Key Discoveries: Halving Urgency and Tripling Deferral Time

By tracking daily electronic diaries and tissue biopsies over 28 weeks, the researchers revealed impressive improvements across all urgency measures:

1. Halving Bowel Urgency Severity: Average urgency severity scores on the UNRS scale dropped by 52 per cent by Week 28, falling from a heavy average score of 6.9 at baseline down to 3.7 at Week 12, and continuing to improve to 3.3 at Week 28.
2. Cutting Urgency Episodes in Half: The daily frequency of urgent toilet trips dropped by 55 per cent. At the start of the study, patients experienced an average of 6.9 urgent episodes per day; by Week 12, this fell to 3.1 episodes per day, and this improvement was maintained through Week 28.
3. Tripling Stool Deferral Time: At baseline, only 4.1 per cent of patients could delay a bowel movement for at least 15 minutes or go 24 hours without urgency. By Week 12, this rose to 15.7 per cent, and by Week 28, nearly 1 in 3 patients (29.7 per cent) achieved this level of control.
4. Progressive Tissue Healing: Camera checks and microscopic tissue samples showed that mucosal healing continued to improve over time. In the colon, combined tissue and visual healing (HEMI) rose from 26.7 per cent at Week 12 to 38.4 per cent at Week 28. Healing was even more pronounced in the rectum, rising to 35.5 per cent.

---

Why This Matters to You as a Patient

If you are managing ulcerative colitis and struggling with unpredictable urgency, this trial offers vital, practical hope for your health and quality of life:

1. Proof That Urgency Is Recognised as a Primary Medical Goal: This study gives you the scientific proof that clinical researchers are now actively testing drugs to solve bowel urgency and give you back control over your daily schedule.
2. More Time and Peace of Mind: Gaining the ability to delay a bowel movement for 15 minutes or longer transforms everyday life. It means you can travel, attend meetings, or go for a walk with far less worry about where the nearest toilet is located.
3. Deep Healing That Builds Over Time: Seeing that tissue healing in the colon and rectum continues to improve between Week 12 and Week 28 reassures you that staying on your prescribed biologic treatment allows your gut lining to repair itself at a deep, microscopic level.

By targeting both bowel urgency and deep mucosal healing, advanced biological therapies are helping restore personal freedom, confidence, and quality of life to people living with ulcerative colitis.